I
Immuneering Corporation (IMRX)
NGM – Real vaqt narxi. Valyuta: USD
5.18
-0.02 (-0.38%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NGM – Real vaqt narxi. Valyuta: USD
5.18
-0.02 (-0.38%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Immuneering Corporation, kechki bosqichdagi onkologiya kompaniyasi, Qo'shma Shtatlarda keng ko'lamdagi rak bemorlari uchun dori vositalarini ishlab chiqadi. Kompaniya IMM-1-104 (atebimetinib) ni ishlab chiqadi, bu RAS yoki RAF mutatsiyalari bilan bog'liq oshqozon osti bezi va mayda hujayrali o'pka rakini o'z ichiga olgan bemorlarni davolash uchun 3-bosqichli klinik sinovda bo'lgan qo'sh MEK inhibitori; IMM-6-415 (envometinib), bu qattiq o'smalari bo'lgan bemorlarni davolash uchun 1/2a-bosqichli klinik sinovda; va bir nechta chuqur tsiklik inhibitorlarni kashf qilish dasturlari. Kompaniya unresectable yoki metastatik RAS-mutantli mayda hujayrali o'pka rakiga ega bemorlarda Libtayo bilan birgalikda atebimetinibni baholash uchun Regeneron Pharmaceuticals bilan klinik ta'minot shartnomalariga ega; va Eli Lilly and Company bilan birgalikda olomorasib bilan birgalikda KRAS G12C-mutantli mayda hujayrali o'pka rakiga ega bemorlarda atebimetinibni baholash uchun. Immuneering Corporation 2008 yilda ro'yxatdan o'tgan va shtab-kvartirasi Kembrij, Massachusetsda joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Benjamin J. Zeskind M.B.A., Ph.D. | Co-Founder, President, CEO & Director |
| Dr. Brett M. Hall Ph.D. | Chief Scientific Officer |
| Dr. Peter King Ph.D. | Head of Discovery & VP |
| Dr. Praveen Nair Ph.D. | Head of Translational Pharmacology & VP |
| Mr. Michael D. Bookman J.D. | Chief Legal Officer & Secretary |
| Mr. Robert J. Carpenter M.B.A., M.S. | Co-Founder & Chair Emeritus |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-04-20 | DEFA14A | imrx-2026additionalproxyma.htm |
| 2026-03-06 | 8-K | imrx-20260306.htm |
| 2026-03-06 | 10-K | imrx-20251231.htm |
| 2026-01-07 | 8-K | imrx-20260107.htm |
| 2025-11-12 | 8-K | imrx-20251112.htm |
| 2025-09-25 | 8-K | tm2526946d1_8k.htm |
| 2025-09-24 | 8-K | tm2526843d1_8k.htm |
| 2025-09-09 | D | |
| 2025-09-04 | CORRESP | filename1.htm |
| 2025-09-03 | S-3 | tm2524971-1_s3.htm |
| Ms. Courtney Dugan | VP and Head of Investor Relations & Corporate Communications |
| Ms. Leah R. Neufeld | Chief People Officer |
| Ms. Mallory Morales CPA | Senior VP of Finance, Chief Accounting Officer & Treasurer |
| Ms. Paula George CPA | Director of Accounting & Operations and Assistant Corporate Controller |